Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
NCT04665206
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor, Adult
- Mesothelioma
- NSCLC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Vivace Therapeutics, Inc
- Last updated on ClinicalTrials.gov
- April 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, CA
Illinois · 1
- University of Chicago Medical Center · Chicago, IL
Massachusetts · 2
- Dana-Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
Minnesota · 1
- M Health Fairview University of Minnesota Medical Center · Minneapolis, MN
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Texas · 2
- MD Anderson Cancer Center · Houston, TX
- NEXT Oncology · San Antonio, TX
Virginia · 1
- Virginia Cancer Specialists, PC · Arlington, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.